Evommune, Inc. (EVMN) income statement
EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
$7.24+0.36 (+5.23%)
Close on Nov 19, 2026Market cap $262.76MP/E –Yield –
Evommune, Inc. financial ratios
See a number that looks wrong?
Close on Nov 19, 2026Market cap $262.76MP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Margins | |||
| Operating margin | -623.6% | -1,000.2% | – |
| EBITDA margin | -619.0% | -993.0% | – |
| Pre-tax margin | -529.8% | -975.8% | – |
| Net profit margin | -529.8% | -954.4% | – |
| Free cash flow margin | -589.8% | -832.6% | – |
| Returns on capital | |||
| Return on equity | -224.6% | 61.6% | – |
| Return on assets | -45.8% | -87.8% | – |
| Return on tangible assets | -45.8% | -87.8% | – |
| Return on capital employed | -63.6% | -145.6% | – |
| NOPAT | -$64.05M | -$55.31M | – |
| Cash flow quality | |||
| OCF / Sales | -588.0% | -831.4% | – |
| OCF / Net income | 1.11 | 0.87 | – |
| FCF / OCF | 100.3% | 100.2% | – |
| FCF / Net income | 1.11 | 0.87 | – |
| FCF / EBITDA | 95.3% | 83.8% | – |
| Unlevered free cash flow | -$76.68M | -$58.28M | – |
| Levered free cash flow | -$76.68M | -$58.28M | – |
| Efficiency | |||
| Asset turnover | 0.09 | 0.09 | – |
| Fixed asset turnover | 11.21 | 5.28 | – |
| CapEx to revenue | 1.8% | 1.3% | – |
| CapEx to OCF | -0.31% | -0.15% | – |
| CapEx to depreciation | 0.39 | 0.18 | – |
| Liquidity | |||
| Current ratio | 8.57 | 2.64 | – |
| Quick ratio | 8.57 | 2.64 | – |
| Cash ratio | 8.33 | 2.58 | – |
| Working capital | $135.57M | $46.01M | – |
| Net current asset value | $134.10M | $45.47M | – |
| Leverage | |||
| Assets to equity | 1.09 | -0.53 | – |
| Per share | |||
| Revenue per share | 0.41 | 4.51 | – |
| EPS (basic) | -11.22 | -45.29 | – |
| EPS (diluted) | -11.22 | -45.29 | – |
| Book value per share | 6.52 | -92.97 | – |
| Tangible book value per share | 6.52 | -92.97 | – |
| Cash per share | 4.73 | 46.57 | – |
| Operating cash flow per share | -2.42 | -37.51 | – |
| Free cash flow per share | -2.43 | -37.57 | – |
| CapEx per share | 0.0075 | 0.06 | – |
| Valuation at period end | |||
| Market cap | $26.62M | – | – |
| Enterprise value | -$49.44M | – | – |
| P/S | 2.0x | – | – |
| P/B | 0.1x | – | – |
| P/TBV | 0.1x | – | – |
| P/OCF | -0.3x | – | – |
| EV/Sales | -3.8x | – | – |
| EV/EBITDA | 0.6x | – | – |
| EV/EBIT | 0.6x | – | – |
| EV/OCF | 0.6x | – | – |
| EV/FCF | 0.6x | – | – |
| Earnings yield | -258.7% | – | – |
| FCF yield | -288.0% | – | – |
| Cost structure | |||
| R&D to revenue | 569.6% | 917.8% | – |
| Stock-based comp to revenue | 45.0% | 24.6% | – |
| Per employee | |||
| Total employees | 48 | 48 | 48 |
| Revenue per employee | $270.83K | $145.83K | – |
| Operating profit per employee | -$1.69M | -$1.46M | – |
| Net income per employee | -$1.43M | -$1.39M | – |
| Free cash flow per employee | -$1.60M | -$1.21M | – |
| Growth | |||
| Revenue 1Y growth | 85.7% | – | – |
| EBIT 1Y growth | -15.8% | – | – |
| EBITDA 1Y growth | -15.8% | – | – |
| Net income 1Y growth | -3.1% | – | – |
| Diluted EPS 1Y growth | 75.2% | – | – |
| Operating cash flow 1Y growth | -31.4% | – | – |
| Free cash flow 1Y growth | -31.6% | – | – |
| CapEx 1Y growth | 167.0% | – | – |
| Total assets 1Y growth | 195.8% | – | – |
| Total equity 1Y growth | 242.5% | -85.6% | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.